1. Amplification of positivity for depression and anxiety: Neural prediction of treatment response.
- Author
-
Kryza-Lacombe M, Spaulding I, Ku CK, Pearson N, Stein MB, and Taylor CT
- Subjects
- Humans, Male, Female, Adult, Young Adult, Middle Aged, Adolescent, Cognitive Behavioral Therapy methods, Depression therapy, Depression psychology, Depression physiopathology, Anxiety therapy, Anxiety psychology, Anxiety physiopathology, Affect physiology, Treatment Outcome, Cues, Brain physiopathology, Brain diagnostic imaging, Anxiety Disorders therapy, Anxiety Disorders physiopathology, Anxiety Disorders psychology, Insular Cortex diagnostic imaging, Insular Cortex physiopathology, Magnetic Resonance Imaging, Motivation physiology
- Abstract
Psychosocial treatments targeting the positive valence system (PVS) in depression and anxiety demonstrate efficacy in enhancing positive affect (PA), but response to treatment varies. We examined whether individual differences in neural activation to positive and negative valence incentive cues underlies differences in benefitting from a PVS-targeted treatment. Individuals with clinically elevated depression and/or anxiety (N = 88, ages 18 to 55) participated in one of two randomized, waitlist-controlled trials of Amplification of Positivity (AMP; NCT02330627, NCT03196544), a cognitive and behavioral intervention targeting the PVS. Participants completed a monetary incentive delay (MID) task during fMRI acquisition at baseline measuring neural activation to the possibility of gaining or losing money. Change in PA from before to after treatment was assessed using the Positive and Negative Affect Schedule. No significant associations were observed between baseline neural activation during gain anticipation and AMP-related changes in PA in regions of interest (striatum and insula) or whole-brain analyses. However, higher baseline striatal and insula activation during loss anticipation was associated with greater increases in PA post-AMP. This study provides preliminary evidence suggesting neural reactivity to negative valence cues may inform who stands to benefit most from treatments targeting the PVS., Competing Interests: Declaration of competing interest Maria Kryza-Lacombe, Isabella Spaulding, Cheuk King Ku, and Nana Pearson declare that they have no conflicts of interest. Charles T. Taylor declares that in the past 3 years he has been a paid consultant for Bionomics and receives payment for editorial work for UpToDate and the journal Depression and Anxiety. Murray B. Stein declares that in the past 3 years he has received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Delix Therapeutics, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). He has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense. He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF